Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific to manufacture the company’s topical ReneCann therapeutic cannabinoid formulation.
ReneCann is a proprietary therapeutic developed to treat dermatological conditions caused by disorders of the immune system, including vitiligo, psoriasis and atopic dermatitis, otherwise known as eczema.
New cannabinoid delivery
“The production of ReneCann adds a new route of cannabinoid delivery to the Incannex portfolio, opening the possibility for direct application of cannabinoid medicines to affected areas in dermatological conditions,” Incannex Healthcare chief scientific officer Dr Mark Bleackley said.
“ReneCann is also Incannex’s first product to incorporate CBG, a minor cannabinoid.
“Expansion into minor cannabinoids provides us the opportunity to explore different activity profiles of this diverse family of molecules across a range of new therapeutic areas.”
The product produced by Eurofins will be leveraged in upcoming clinical trials confirming the safety and efficacy of ReneCann, the data from which will aid in passing regulatory hurdles and assessing potential for other topical treatment indications.
Vitiligo results particularly encouraging
Incannex previously conducted a concept study for an earlier version of ReneCann at the Maurits Clinic, The Netherlands, led by world-renowned dermatologist Dr Marcus Meinardi, PhD, MD.
Patients with vitiligo, psoriasis and atopic dermatitis experienced improvements in symptoms of 10%, 33% and 22% respectively.
IHL is particularly interested in the therapy’s application in vitiligo, as the disease’s incidence is quite high (0.5-1.0% of the global population) and treatment options are limited.
Read more on Proactive Investors AU